Skip to content
Screener

Cytokinetics CYTK Income Statement

Q2 '26Q1 '26Q4 '25Q3 '25Q2 '25
Total revenue
$28.62M-57.1%$19.36M+1,126%$17.76M+4.9%$1.94M+318%$66.77M+26,715%
Research and development
$97.81M-11.2%$95.53M-2.8%$104.4M+11.5%$99.23M+17.3%$110.14M+38.4%
Selling, general and administrative
$104.4M+58.8%$104.9M+82.8%————$65.72M—
Total operating expenses
$207.8M+16.6%$202.97M+29.1%$196.12M+25.7%$168.69M+19.4%$178.28M+36.7%
Operating income
-$179.17M-60.7%-$183.62M-18.0%-$178.37M-28.3%-$166.76M-18.4%-$111.51M+14.3%
Operating margin
-626%-459pp-948.7%+8,908pp-1,004.6%-183pp-8,613.4%+21,797pp-167%+52,111pp
Interest expense
$14.65M+32.2%$14.52M+63.7%$14.27M+59.7%$11.35M+27.2%$11.08M-12.9%
Other income (expense), net
$13.94M+7.2%$11.02M-19.6%$11.47M-23.6%$10.25M-39.9%$13M+12.5%
Net income
-$198.76M-47.9%-$206.03M-27.7%-$183.03M-22.0%-$306.18M-90.7%-$134.37M+6.2%
Net margin
-694.4%-493pp-1,064.5%+9,156pp-1,030.9%-145pp-15,815%+18,860pp-201.2%+57,356pp
Diluted earnings per share
-$1.50-33.9%-$1.67-22.8%-$1.50-19.0%-$2.55-87.5%-$1.12+14.5%
EBITDA
-$175.54M-60.7%-$180.24M-17.5%-$175.51M-28.4%-$164.08M-18.6%-$109.22M+14.5%
EBITDA margin
-613.3%-450pp-931.2%+8,779pp-988.5%-181pp-8,475%+21,415pp-163.6%+51,148pp
EBIT
-$179.17M-60.7%-$183.62M-18.0%-$178.37M-28.3%-$166.76M-18.4%-$111.51M+14.3%

FAQ

What is Cytokinetics's revenue?
Cytokinetics (CYTK) generated $67.7M in revenue over the trailing twelve months, down 21.1% year over year.
Is Cytokinetics profitable?
Cytokinetics is not currently profitable: it reported a net loss of $894.0M over the trailing twelve months, a -1321.1% net margin.
What is Cytokinetics's earnings per share?
Cytokinetics's diluted EPS over the trailing twelve months is $-7.22.
Where does Cytokinetics's income statement data come from?
Every line is extracted from Cytokinetics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.